Provided by Tiger Fintech (Singapore) Pte. Ltd.

Esperion Therapeutics

0.9492
+0.01952.10%
Pre-market: 1.060.1108+11.67%04:43 EDT
Volume:4.93M
Turnover:4.79M
Market Cap:187.80M
PE:-3.43
High:1.06
Open:0.9813
Low:0.9300
Close:0.9297
Loading ...

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Nov 2024

Esperion highlights exploratory data from CLEAR outcomes trial of Nexletol

TIPRANKS
·
18 Nov 2024

Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
09 Nov 2024

Esperion Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
08 Nov 2024

Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

GuruFocus.com
·
08 Nov 2024

Esperion Therapeutics Sees Significant Revenue Growth in Q3 2024

TIPRANKS
·
08 Nov 2024

Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Zacks
·
07 Nov 2024

Esperion Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
07 Nov 2024

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
07 Nov 2024

Esperion Therapeutics: Q3 Earnings Snapshot

Associated Press Finance
·
07 Nov 2024

Esperion Therapeutics Q3 2024 GAAP EPS $(0.15) Beats $(0.17) Estimate, Sales $51.63M Beat $51.32M Estimate

Benzinga
·
07 Nov 2024

BRIEF-Esperion Therapeutics Q3 Basic EPS USD -0.15

Reuters
·
07 Nov 2024

Esperion Therapeutics Q3 Net Income USD -29.524 Million

THOMSON REUTERS
·
07 Nov 2024

Esperion Therapeutics Q3 Operating Expenses USD 67.658 Million

THOMSON REUTERS
·
07 Nov 2024

Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
31 Oct 2024

Bank of America Securities Keeps Their Sell Rating on Esperion (ESPR)

TIPRANKS
·
28 Oct 2024